Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

• Status: Completed
• Trial end date: 2019-09-25
• Target enrollment: 0
• Participant gender: All

Summary

Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: BMS-986165

Criteria

Inclusion Criteria:

• Signed Informed Consent.

• Healthy participants, as determined by physical examination, ECGs, and clinical laboratory and procedure determinations.

• Body mass index (BMI) of 18 to 24 kg/m2, inclusive, and total body weight >= 50 kg.

Exclusion Criteria:

• History of allergy to drug class or related compounds.

• History or evidence of active infection within 7 days of study day 1.

• Drug or alcohol abuse within 6 months of study treatment administration.

Other protocol defined inclusion/exclusion criteria could apply